Acting On Peptide Bonds (3.4) (e.g., Urokinease, Etc.) Patents (Class 424/94.63)
  • Patent number: 11491186
    Abstract: The present invention provides therapeutic products with decreased fibrinolytic activity of t-PA-deficient and/or plasminogen-deficient blood products, as well as compositions, kits and methods using the same in treating bleeding associated with hereditary or acquired bleeding disorders. The invention further provides extracorporeal apparatus for blood or blood products Plasmapheresis aimed to prevent or treat bleeding disorders.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: November 8, 2022
    Assignee: PLAS-FREE LTD
    Inventors: Abd Alrauf Hijazi, Muhamed Higazi
  • Patent number: 11484523
    Abstract: A composition for mitigating, treating, and/or preventing symptoms associated with veisalgia. In one embodiment the composition comprises one or more ingredients selected from the group consisting of: dihydromyricetin, N-acetyl cysteine, salicin, quercetin, bromelain, opuntia, potassium, sodium, magnesium, B-vitamins, vitamin C, taurine, caffeine, monk fruit, turmeric, curcumin, ginger root, and black pepper extract. A method for treating symptoms associated with veisalgia is also described. In one embodiment, the composition is administered in liquid or pill form.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: November 1, 2022
    Assignee: Purple Biosciences LLC
    Inventor: Monir Elias
  • Patent number: 11434468
    Abstract: The invention relates to a lactic acid bacterium (LAB), Lactobacillus fermentum PS150, and a bioactive protein produced by the LAB, which has an advantageous effect in improving mood disorder, enhancing cognitive functions in brain and treating or preventing a neurodegenerative disease.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: September 6, 2022
    Assignee: Bened Biomedical Co., Ltd.
    Inventors: Mintze Liong, Ying-Chieh Tsai, Matthew Cheeyuen Gan, Sawibah Yahya, Sybing Choi, Jiasin Ong, Waiyee Low, Chih-Chieh Hsu, Yi-Shan Lee
  • Patent number: 11413300
    Abstract: Methods are disclosed for the reduction or elimination of bacterial biofilms on biological and non-biological surfaces, as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms using compositions comprising a synergistic combination of thermolysin and at least one aminoglycoside antibacterial agent.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: August 16, 2022
    Assignee: SMITH & NEPHEW, INC.
    Inventors: Aleksa Jovanovic, Lei Shi, Eric Roche, Paul Renick
  • Patent number: 11364287
    Abstract: Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of Celiac Disease. Also described herein is a method for treating a subject with Celiac Disease using digestive enzymes and their derivatives to alleviate the symptoms of Celiac Disease. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of Celiac Disease.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: June 21, 2022
    Assignee: CUREMARK, LLC
    Inventors: Joan M. Fallon, Matthew F. Heil, James Szigethy, James J. Fallon
  • Patent number: 11351235
    Abstract: Autologous anti-cancer vaccines and methods of manufacture and treatment are provided, including expansion of individual patient-derived tumor cells in an immune-compromised animal(s) to attain, quantitatively and qualitatively, sufficient material for efficacious vaccine production and utilization, to elicit an immune response against micrometastases and/or recurrence in the individual patient following tumor excision.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: June 7, 2022
    Inventor: Michael G. Hanna, Jr.
  • Patent number: 11338022
    Abstract: The present invention relates to the effect of plasminogen in the treatment and/or elimination of angiocardiopathy, especially angiocardiopathy caused by diabetes mellitus, thereby providing a new strategy for treating different kinds of angiocardiopathy, especially angiocardiopathy and its related disorders caused by diabetes mellitus.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: May 24, 2022
    Assignee: TALENGEN INTERNATIONAL LIMITED
    Inventor: Jinan Li
  • Patent number: 11320422
    Abstract: Disclosed herein are methods and compositions useful for evaluating, selecting, identifying, or making a cell or cell line that has improved production capacity for generating higher yields of products and/or improved capacity to produce higher quality products. Products, as described herein, can include a polypeptide that is endogenously expressed by the cell, a recombinant polypeptide that is not endogenously expressed, or a non-naturally occurring recombinant polypeptide. The methods described herein include modulating, e.g., inhibiting, the protein degradation pathway by using a proteasome inhibitor, an ER-associated degradation (ERAD) inhibitor, or a ubiquitin pathway inhibitor.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: May 3, 2022
    Assignee: Lonza Ltd.
    Inventors: Colin Mark Jaques, Christopher Mark Smales, Tanya Jeane Knight
  • Patent number: 11292759
    Abstract: Hydroxycitric acid-metal heterocyclic compounds with covalent characteristics are provided. The subject hydroxycitric acid compounds include monomeric hydroxycitric acid (HCA) compounds having a divalent metal, lactone forms thereof, and dimeric compound forms thereof. The monomeric HCA compound includes a divalent metal (X) bonded via a 5-membered ring to both the carboxylic acid and the hydroxy group of the central C2 carbon of the HCA. In addition, a monovalent metal (Y) can also be bonded to the carboxylic acid of C3 or C1, or to both C1 and C3. The subject dimeric compounds include monomeric HCA compounds linked via a second divalent metal (X) to a carboxylic acid group of each HCA unit at C3 or C1. Also provided are compositions including a monomeric HCA compound and one or more other additional compounds. Methods of alleviating at least one symptom associated with a target disease or condition in a subject are provided.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: April 5, 2022
    Assignee: Nutrition Research Group, Limited
    Inventors: Daniel E. Clouatre, Nimpan Bangun, Dallas L. Clouatre
  • Patent number: 11214782
    Abstract: The disclosure relates, in general, to Glycogen Storage Disease Type VI and, in particular, to a method of treating Glycogen Storage Disease Type VI and to compounds and compositions suitable for use in such a method.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: January 4, 2022
    Assignee: Duke University
    Inventors: Yuan-Tsong Chen, Priya Kishnani, Baodong Sun
  • Patent number: 11214783
    Abstract: The present invention concerns a method for selectively activating a thermostable hydrolase at a temperature above T1. The present invention provides compositions comprising a thermostable hydrolase and a temperature sensitive inhibitor, wherein said thermostable hydrolase and said temperature sensitive inhibitor form a hydrolase-inhibitor complex at a temperature below T1, but which dissociates at a temperature of about T1. The present invention also relates to uses of said compositions, and a method for preparing said compositions.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: January 4, 2022
    Assignee: PURATOS NV
    Inventors: Geertrui Bosmans, Ellen Fierens, Kristof Brijs, Jan Delcour, Fabienne Verte, Jacques Georis, Valérie Dorgeo, Filip Arnaut
  • Patent number: 11191818
    Abstract: The disclosure provides compositions and methods for treating, ameliorating, and/or preventing a vaso-occlusive crisis (VOC) in a subject suffering from sickle cell disease (SCD). The disclosure also provides compositions and methods for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS). The disclosure provides A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13) or a composition comprising ADAMTS13 for treating, ameliorating, and/or preventing the VOC, or for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from ALI and/or ARDS.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: December 7, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Bruce Ewenstein, Brahm Goldstein, Bernhard Majer, Paolo Rossato, Friedrich Scheiflinger, Marietta Turecek
  • Patent number: 11124766
    Abstract: This disclosure relates to growth media and environments for in vitro culturing of cells that produce or are capable of producing antibodies. In certain embodiments, the media comprises IL-6, fibronectin, and typically a saccharide. In certain embodiments, the disclosure contemplates cell culture compositions comprising IL-6 and fibronectin that are derived from proteins secreted from mesenchymal stromal/stem cells (MSCs). In certain embodiments, the disclosure contemplates enclosures comprising culture compositions disclosed herein that are in ambient air or optionally in an environment wherein oxygen is absent or at a low concentration.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: September 21, 2021
    Inventors: Frances Eun-Hyung Lee, Ignacio Sanz, Doan Nguyen
  • Patent number: 11090248
    Abstract: The present disclosure provides compositions which may be used to augment, supplement and/or replace the products of certain UV sensitive/dependent processes. In particular, the disclosure provides sunscreen compositions which avoid problems associated with prior art sunscreen compositions which inhibit the natural progression of certain in vivo sunlight/UV dependent processes including processes which result in Nitric Oxide/Vitamin D production in the skin.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: August 17, 2021
    Assignee: DR WELLER LIMITED
    Inventor: Mike Finnen
  • Patent number: 11091751
    Abstract: The present invention relates to a method for the recombinant production of a serine protease comprising (a) culturing a host cell comprising one or more vectors, wherein the one or more vectors encode in expressible form the serine protease and a proteinaceous inhibitor of the serine protease, wherein the proteinaceous inhibitor of the serine protease is heterologous with respect to the serine protease, under conditions wherein the serine protease and the proteinaceous inhibitor of the serine protease are expressed; or (a?) culturing a host cell the genome of which encodes in expressible form the serine protease and a proteinaceous inhibitor of the serine protease, wherein the proteinaceous inhibitor of the serine protease is heterologous with respect to the serine protease, and wherein the coding sequences of the serine protease and/or the proteinaceous inhibitor have been introduced into the host cell genome by applying a CRISPR technology, under conditions wherein the serine protease and the proteinaceous
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: August 17, 2021
    Assignee: BRAIN Biotech AG
    Inventors: Alexander Pelzer, Bela Kelety
  • Patent number: 11077226
    Abstract: Tissue repair and restoration can be performed using an elastic material formed from tropoelastin. The elastic material can be formed by providing a solution of tropoelastin monomers, applying the solution to a surface, and heating the solution on the surface in absence of a cross-linking agent to enable the tropoelastin monomers to bind to each other to form an elastic material that does not dissociate into tropoelastin monomers when the elastic material is contacted with an aqueous solution.
    Type: Grant
    Filed: July 23, 2020
    Date of Patent: August 3, 2021
    Assignee: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
    Inventors: Anthony Steven Weiss, Suzanne Marie Mithieux
  • Patent number: 10973890
    Abstract: Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof, and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose, sucrose.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: April 13, 2021
    Assignee: Allergan, Inc.
    Inventors: Maurice Abiad, Bhas Dani, Evgenyi Shalaev
  • Patent number: 10968253
    Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: April 6, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ECOLE NORMALE SUPERIEURE DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1
    Inventors: Théophile Ohlmann, Philippe Mangeot, Emiliano Ricci
  • Patent number: 10897921
    Abstract: A method is disclosed for making palatable methionine-restricted foods, to deliver a methionine-restricted diet to human or veterinary patients. A protein or a food product containing protein is partially oxidized, preferably with ozone, to oxidize nearly all of the methionine and cysteine. After oxidation, tryptophan and lysine are optionally added back since they tend to be oxidized also. Optionally, a small amount of methionine is also added back so that the final methionine is within a preferred range of about 0.85 to about 1.8 gram methionine per 100 gram total protein, preferably about 1.2 gram per 100 gram total protein.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: January 26, 2021
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: John W. Finley, Thomas Gettys, Frank L. Greenway
  • Patent number: 10881717
    Abstract: The present disclosure relates to a method for increasing the stability of a Factor VIII molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the Factor VIII molecule into a first fragment comprising essentially the A1 domain and the A2 domain and a second fragment comprising essentially the A3 domain, the C1 domain and the C2 domain throughout manufacturing the Factor VIII molecule. The disclosure further pertains to a method for improving the bioavailability of Factor VIII after intravenous and non-intravenous injection.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: January 5, 2021
    Assignee: CSL Limited
    Inventors: Carsten Horn, Sabine Zollner, Hubert Metzner, Stefan Schulte
  • Patent number: 10874721
    Abstract: The present invention relates to the use of plasminogen in the treatment of cervical erosion. Compared to other existing drugs for treating cervical erosion, the plasminogen or plasmin of the present invention can promote the inflammatory repair of damaged mucosa. Therefore, plasminogen may become a novel strategy to treat cervical erosion.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: December 29, 2020
    Assignee: Talengen International Limited
    Inventor: Jinan Li
  • Patent number: 10828276
    Abstract: Embodiments of the present invention are directed to the administration of bryostatins and bryostatins and retinoids for the treatment of disease responsive to increases in alpha secretase activity. Inventions of the present application are directed to the treatment of neuro-degenerative diseases such as Hutchinson Disease, Parkinson's disease, Down's syndrome and Alzheimer's disease and virus latency diseases such as HIV and Herpes, cancers such as prostate, melanomas, lymphomas and renal cancers, esophageal and opthalmic diseases such as glaucoma.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: November 10, 2020
    Inventor: Trevor Percival Castor
  • Patent number: 10744190
    Abstract: The present invention relates to a modified polypeptide comprising a non-cytotoxic protease, a translocation domain, a destructive protease cleavage site and a Targeting Moiety that binds to a Binding Site on a nerve cell, wherein after cleavage of the destructive cleavage site the polypeptide has reduced potency. The destructive cleavage site is recognised and cleaved by a protease present at or in an off-site target cell, and, in one embodiment, the polypeptide is a modified clostridial neurotoxin. The present invention also relates to the use of said polypeptides for treating a range of conditions, and to nucleic acids encoding said polypeptides.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: August 18, 2020
    Assignee: IPSEN BIOINNOVATION LIMITED
    Inventors: John Andrew Chaddock, Keith Alan Foster
  • Patent number: 10709771
    Abstract: The present invention relates to the effect of plasminogen in the prevention or treatment of retinopathy caused by diabetes mellitus, thereby providing a new therapeutic strategy for treating different types of diabetes mellitus-related retinopathy.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: July 14, 2020
    Assignee: TALENGEN INTERNATIONAL LIMITED
    Inventor: Jinan Li
  • Patent number: 10711178
    Abstract: A composition and a method to improve the exploit of oil from a hydrocarbon containing formation are disclosed. The method is characterized in that a aqueous composition including extract of a plant is injected into the formation to reduce the interfacial tension between the oil trapped in the formation and water, and the oil in said aqueous mixture is recovered for further use. Preferably, the aqueous mixture injected comprises an interfacial tension reducing composition made from a plant extract based on a plant family to which the plants Ziziphus Spina Christi and Aloe Vera belong. In particular the injection mixture also comprises at least one of the following constituents: fructose, sucrose, maltose, proteins, lipids and saponins.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: July 14, 2020
    Assignee: Abu Dhabi University
    Inventor: Omar Chaalal
  • Patent number: 10648044
    Abstract: This document relates to molecular complexes having acid alpha glucosidase activity and at least one modification that results in enhanced ability of the molecular complex to be transported to the interior of a mammalian cell.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: May 12, 2020
    Assignee: Oxyrane UK Limited
    Inventors: Wouter Vervecken, Kathleen Camilla Telesphore Alida Maria Piens, Jan Robert Ludo Stout, Gwenda Noëlla Pynaert
  • Patent number: 10611799
    Abstract: An anti-endotoxin polypeptide is provided. The anti-endotoxin polypeptide having the formula (I) A1-L-C1, wherein A1 and C1 independently is a short peptide with ?-helix, L is AGP (Ala-Gly-Pro) or a peptide bond, and the hydrophobicity of the hydrophobic terminus in the anti-endotoxin polypeptide is between about 0.425 and 0.765. The anti-endotoxin polypeptide of the invention can neutralize the lipopolysaccharide and has the low hemolysis and high salt resistance, simultaneously. The present invention also provides a method for design an anti-endotoxin polypeptide, the anti-endotoxic activity is adjusted through increasing and/or decreasing hydrophobicity of the hydrophobic terminal end.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: April 7, 2020
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventors: Jya-Wei Cheng, Hung-Lun Chu, Ya-Han Chih, Hui-Yuan Yu
  • Patent number: 10590402
    Abstract: Disclosed is a combination of two or more lipase enzymes, and its use for treating a lipid digestion deficiency and/or a digestive disorder. At least one lipase enzyme has a pH optimum at an acidic pH value, while at least one other lipase enzyme has a pH optimum at an alkalic pH value.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: March 17, 2020
    Assignee: CILIAN AG
    Inventors: Marcus Wolf William Hartmann, Ingo Aldag
  • Patent number: 10556037
    Abstract: The present invention is directed to topical enzymatic wound debriding compositions with enhanced enzymatic activity. These compositions comprise a dispersed phase comprising at least one proteolytic enzyme and at least one hydrophilic polyol; and a continuous phase comprising a hydrophobic base.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: February 11, 2020
    Assignee: Smith & Nephew, Inc.
    Inventors: Lei Shi, Aleksa Jovanovic, Duncan Aust
  • Patent number: 10550380
    Abstract: The present invention concerns a method for selectively activating a thermostable hydrolase at a temperature above T1. The present invention provides compositions comprising a thermostable hydrolase and a temperature sensitive inhibitor, wherein said thermostable hydrolase and said temperature sensitive inhibitor form a hydrolase-inhibitor complex at a temperature below T1, but which dissociates at a temperature of about T1. The present invention also relates to uses of said compositions, and a method for preparing said compositions.
    Type: Grant
    Filed: November 26, 2015
    Date of Patent: February 4, 2020
    Assignee: PURATOS NV
    Inventors: Geertrui Bosmans, Ellen Fierens, Kristof Brijs, Jan Delcour, Fabienne Verte, Jacques Georis, Valérie Dorgeo, Filip Arnaut
  • Patent number: 10544408
    Abstract: The present invention relates to a novel process of isolating and purifying tissue plasminogen activator and its variants more specifically TNK-tPA from CHO cells and describes an industrially applicable, simple, cost effective, robust and highly efficient process of TNK-tPA purification.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: January 28, 2020
    Assignee: GENNOVA BIOPHARMACEUTICALS LIMITED
    Inventors: Arjun Raghuwanshi, Shrawan Singh Kumar, Ankit Kumar, Mihir Sahoo Ranjan, Sanjay Singh
  • Patent number: 10450554
    Abstract: The present invention relates to a polypeptide having proline-specific endoprotease activity, selected from the group consisting of i. a polypeptide comprising a mature polypeptide sequence of SEQ ID NO: 2; ii. a polypeptide that has least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to the mature polypeptide sequence of SEQ ID NO: 2; iii. a polypeptide encoded by a nucleic acid that hybridizes under medium stringency, preferably under high stringency conditions to the complementary strand of the mature polypeptide coding sequence of SEQ ID NO:1; iv. a polypeptide encoded by a nucleic acid that has at least 70%, 75% 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the mature polypeptide coding sequence of SEQ ID NO: 1. The invention further relates to a method of producing the polypeptide and a process for the preparation of a food or feed product wherein the polypeptide is used.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: October 22, 2019
    Assignee: DSM IP ASSETS B.V.
    Inventors: Jan Metske Van Der Laan, Peter Jozef Ida Van De Vondervoort, Chantal Christis, Martine Spaans, Angela De Bruine-Paulus, Johanna Henrica Gerdina Maria Mutsaers
  • Patent number: 10392609
    Abstract: Described herein are methods and genetically engineered cells useful for uncapping a mannose-6-phosphate residue on an oligosaccharide.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: August 27, 2019
    Assignees: Oxyrane UK Limited, VIB vzw, Universiteit Gent, Vrije Universiteit Brussel
    Inventors: Nico Luc Marc Callewaert, Wouter Vervecken, Petra Sophie Tiels, Han Karel Remaut, Kathleen Camilla Telesphore Alida Maria Piens
  • Patent number: 10370718
    Abstract: Provided herein are methods of adjusting or selecting a gluten peptide therapy based on the human leukocyte antigen (HLA) genotype, in particular HLA-DQ2.5 homozygosity, of a subject having or suspected of having Celiac disease. Also provided herein are methods of identifying (e.g., diagnosing) a subject, such as a subject having or suspected of having Celiac disease and/or assessing the efficacy of treatment of Celiac disease, e.g. by determining responsiveness to a therapeutic gluten peptide composition or cytokine response, and kits relating thereto.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: August 6, 2019
    Assignee: ImmusanT, Inc.
    Inventor: Robert P. Anderson
  • Patent number: 10344333
    Abstract: Systems, methods, and computer readable media for diagnosing or characterizing a genetic predisposition to develop cancer are provided. Nucleic acids comprising a germline nucleic acid sequence encoding the BRCA1 associated protein 1 are sequenced or probed to determine if the nucleic acid sequence includes alterations that predispose a subject to develop cancer.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: July 9, 2019
    Assignees: Institute For Cancer Research, University of Hawaii
    Inventors: Joseph R. Testa, Michele Carbone, Mitchell Cheung, Jianming Pei
  • Patent number: 10285922
    Abstract: An aqueous formulation for topical chemical exfoliation to the skin containing purified water, polyacrylic acid, disodium ethylenediaminetetraacetate, glycerin, specially denatured alcohol, dimethicone, cetyltrimethylammonium chloride, papain enzyme, citrus seed extract, and a nontoxic preservative. The formulation may further contain benzylalcohol and dehydroacetic acid which serve as effective nontoxic preservatives. The exfoliating formulations of the invention are useful in the removal of the surface layer of the skin and in particular, the dead cells of the stratum corneum. The formulation may be retained in an air tight vessel such as a syringe. About 5 rads to about 10 rads of gamma radiation may be applied to the formulation retained within the air tight vessel.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: May 14, 2019
    Inventor: Bruce Wayne Miller
  • Patent number: 10150803
    Abstract: The present invention relates a method of preparing a Glucagon-like peptide 2 (GLP-2) analog by gene recombination. The present invention provides an expression vector, which includes: (a) a nucleic acid sequence encoding tag protein; (b) a nucleic acid sequence encoding Smt3 protein (SEQ ID NO: 1); and (c) a nucleic acid sequence encoding linker peptide (SEQ ID NO: 2) and GLP-2 analog. The fusion protein expressed by the expression vector can be cleaved by thrombin, wherein the cleaving position is at the linker peptide, and then the GLP-2 analog is produced.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: December 11, 2018
    Assignee: CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO. LTD
    Inventors: Shih-Lin Chen, Ting-Yu Hsiung
  • Patent number: 10100296
    Abstract: The present invention provides compositions for use in the prophylaxis or treatment of a condition arising from gluten intolerance, the compositions including at least partially purified caricain (or a biologically active fragment, analog or variant thereof) alone or in combination with other suitable enzymes including bromelain, and/or an intestinal extract, as herein described. The present invention also provides methods of using such compositions for the prophylaxis or treatment of a condition arising from gluten intolerance.
    Type: Grant
    Filed: January 6, 2010
    Date of Patent: October 16, 2018
    Assignee: Glutagen Pty Ltd
    Inventors: Teodor Stelmasiak, Hugh James Beatty Cornell
  • Patent number: 9949489
    Abstract: Compositions having at least one compound which inhibits the formation of Hemipteran stylet sheaths and/or degrades hemipteran style sheaths that have already been formed, and thus deters or blocks hemipteran insects from feeding on plants, especially agriculturally important plants and methods of use of such compositions are described. Such compositions can be applied onto plants by spraying, dripping, or other methods and/or can be applied to the soil for uptake by the roots. These compositions and methods prevent and/or reduce the transmission of vascular associated diseases (caused by hemipteran vector-borne pathogens) to plants.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: April 24, 2018
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Robert G. Shatters, Gary A. Luzio, John K. Morgan
  • Patent number: 9932569
    Abstract: Provided herein are antibacterial compositions and methods of making and using the compositions.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: April 3, 2018
    Assignee: GangaGen, Inc.
    Inventors: Chemira B Appaiah, Sriram Padmanabhan, R. Sanjeev Saravana, Bharathi Sriram
  • Patent number: 9907798
    Abstract: Methods of treating a head and neck cancer are disclosed.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: March 6, 2018
    Assignees: FOUNDATION MEDICINE, INC., UCL Business PLC
    Inventors: Chris Hendrik Boshoff, Timothy Robert Fenton, Matthias Alexander Lechner, Philip James Stephens, Matthew J. Hawryluk, Garrett Michael Frampton, Roman Yelensky
  • Patent number: 9901626
    Abstract: A method is disclosed to dissolve protein deposited in muscle. The method includes the step of administering an effective amount of an agent selected from the group consisting of fibrinolytics, proteolytics, photolytic and magnelytic agents.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: February 27, 2018
    Inventor: G. Blair Lamb
  • Patent number: 9879246
    Abstract: The present invention provides a fibrinolytic composition useful as a therapeutic for administration to a patient having a thrombotic occlusion. In one aspect of the present invention, the fibrinolytic composition comprises a reversibly inactivated acidified serine protease substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent. In another aspect of the invention, the fibrinolytic composition of the present invention comprises a reversibly inactivated acidified plasmin substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: January 30, 2018
    Assignee: Grifols Therapeutics Inc.
    Inventors: Thomas P Zimmerman, Valery Novokhatny, Shan Jiang, James D Colandene
  • Patent number: 9850500
    Abstract: The present invention relates to a recombinant adenovirus capable of regulating angiogenesis, which comprises (a) an adenoviral UR (inverted terminal repeat) nucleotide sequence; and (b) a transcription regulatory sequence for a VEGF-A (vascular endothelial growth factor-A) gene comprising (i) a nucleotide sequence encoding a DNA binding domain comprising a zinc finger domain to bind to a site in a VEGF-A promoter sequence as set forth in nucleotides 1-2362 of SEQ ID NO:1, and (ii) a transcription activation domain or a transcription inhibitory domain linked to the nucleotide sequence encoding the DNA binding domain; and a pharmaceutical composition comprising the recombinant adenovirus.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: December 26, 2017
    Inventors: Chae-Ok Yun, Joo-Hang Kim, Jin Soo Kim, Hyun Chul Shin, Yoon A Kang
  • Patent number: 9797895
    Abstract: The present invention relates to the use of a composition comprising (a) at least three different amino acids, (b) at least two different amino acids and a saponin or (c) at least one dipeptide or tripeptide for stabilizing biomolecules immobilized on a solid carrier. The invention furthermore relates to a method for producing stabilized biomolecules, comprising embedding the biomolecules in the composition according to the invention and a method of producing a solid carrier having biomolecules attached thereto. The invention furthermore relates to a solid carrier producible or produced by the method of the invention and a method of diagnosing a disease using the carrier of the invention.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: October 24, 2017
    Assignee: Leukocare AG
    Inventors: Stefan Margraf, Anja Breuer, Martin Scholz, Jens Altrichter
  • Patent number: 9757433
    Abstract: The present invention relates to modified angiotensin converting enzyme 2 (ACE2) polypeptides and pharmaceutical and analytical uses thereof. In particular, the present invention relates to Zn2+ depleted-, Zn2+ free-, mixed metal- and metal ion substituted-ACE2 as well as methods for the manufacture of these variants and uses thereof, such as therapeutic and analytic uses of these ACE2 variants.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: September 12, 2017
    Assignee: Apeiron Biologicals AG
    Inventors: Hans Loibner, Bernhard Peball, Manfred Schuster, Stefan Stranner
  • Patent number: 9636385
    Abstract: Provided is a method of treatment for reducing fibrosis involving administering purified collagenase into an anterior chamber of an eye of a human patient.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: May 2, 2017
    Assignee: The Research Foundation for The State University of New York
    Inventor: Robert Honkanen
  • Patent number: 9611467
    Abstract: This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: April 4, 2017
    Assignees: BAXALTA GMBH, BAXALTA INCORPORATED
    Inventors: Alexandra Nathalie Kopic, Werner Höllriegl, Barbara Plaimauer, Hanspeter Rottensteiner, Eva-Maria Muchitsch
  • Patent number: 9605250
    Abstract: Provided herein are antibacterial compositions and methods of making and using the compositions.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: March 28, 2017
    Assignee: Gangagen, Inc.
    Inventors: Chemira B. Appaiah, Sriram Padmanabhan, R. Sanjeev Saravanan, Bharathi Sriram
  • Patent number: 9572866
    Abstract: Disclosed are polypeptides that are analogs of urocortin 2 that have pharmacological activity similar to urocortin 2 but have improved water solubility compared to urocortin 2, and pharmaceutical compositions of the polypeptides of the present invention. Also disclosed are polynucleotides encoding the polypeptides, and methods of treating pathophysiological states employing pharmaceutical compositions of the polypeptides and polynucleotides of the present invention. In addition, disclosed are vectors and host cells that include a nucleic acid encoding a polypeptide of the present invention, and kits that include pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: February 21, 2017
    Assignee: Research Development Foundation
    Inventors: Wylie W. Vale, Jr., Joan M. Vaughan, Cindy Donaldson, Wolfgang Fischer, Jean E. F. Rivier